» Articles » PMID: 36302379

Dysfunctional Microglia and Tau Pathology in Alzheimer's Disease

Overview
Journal Rev Neurosci
Publisher De Gruyter
Specialty Neurology
Date 2022 Oct 27
PMID 36302379
Authors
Affiliations
Soon will be listed here.
Abstract

Extensive human studies and animal models show that chronic immune system stimulation involving microglia, inflammasome, complement activation, synthesis of cytokines, and reactive oxygen species exacerbates neurodegeneration in Alzheimer's disease (AD) and other tauopathies. Abnormalities in tau, Aβ, and microglial activation are frequently observed in dementia patients and indicate that these elements may work in concert to cause cognitive impairment. Contradicting reports from postmortem studies demonstrating the presence of Aβ aggregates in the brains of cognitively healthy individuals, as well as other investigations, show that tau aggregation is more strongly associated with synapse loss, neurodegeneration, and cognitive decline than amyloid pathology. Tau association with microtubules' surface promotes their growth and maintains their assembly, dynamicity, and stability. In contrast, the reduced affinity of hyperphosphorylated and mislocalized tau to microtubules leads to axonal deficits and neurofibrillary tangles (NFTs). Loss of microglial neuroprotective and phagocytic functions, as indicated by the faulty clearance of amyloid plaques, as well as correlations between microglial activation and tau tangle spread, all demonstrate the critical involvement of malfunctioning microglia in driving tau propagation. This review discusses the recent reports on the contribution of microglial cells to the development and progression of tau pathology. The detailed study of pathogenic mechanisms involved in interactions between neuroinflammation and tau spread is critical in identifying the targets for efficacious treatment strategies in AD.

Citing Articles

Evaluation of altered cell-cell communication between glia and neurons in the hippocampus of 3xTg-AD mice at two time points.

Soelter T, Howton T, Wilk E, Whitlock J, Clark A, Birnbaum A J Cell Commun Signal. 2025; 19(1):e70006.

PMID: 40026671 PMC: 11870853. DOI: 10.1002/ccs3.70006.


Beyond Amyloid and Tau: The Critical Role of Microglia in Alzheimer's Disease Therapeutics.

Dias D, Socodato R Biomedicines. 2025; 13(2).

PMID: 40002692 PMC: 11852436. DOI: 10.3390/biomedicines13020279.


The MR1/MAIT cell axis enhances dystrophic neurite development in Alzheimer's disease.

Wyatt-Johnson S, Ackley S, Warren J, Priya R, Wan J, Liu S Alzheimers Dement. 2025; 21(2):e14480.

PMID: 39777865 PMC: 11848147. DOI: 10.1002/alz.14480.


Targeting Microglia in Alzheimer's Disease: Pathogenesis and Potential Therapeutic Strategies.

Sun Z, Zhang X, So K, Jiang W, Chiu K Biomolecules. 2024; 14(7).

PMID: 39062547 PMC: 11274940. DOI: 10.3390/biom14070833.


Evaluation of altered cell-cell communication between glia and neurons in the hippocampus of 3xTg-AD mice at two time points.

Soelter T, Howton T, Wilk E, Whitlock J, Clark A, Birnbaum A bioRxiv. 2024; .

PMID: 38826305 PMC: 11142088. DOI: 10.1101/2024.05.21.595199.